• Je něco špatně v tomto záznamu ?

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes

E. Franek, M. Haluzík, S. Canecki Varžić, M. Sargin, S. Macura, J. Zacho, JS. Christiansen,

. 2016 ; 33 (4) : 497-505. [pub] 20151117

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000976

AIM: To evaluate the efficacy and safety of twice-daily insulin degludec/insulin aspart vs. twice-daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naïve to insulin. METHODS: In this 26-week, multinational, open-label, controlled, two-arm, parallel-group, treat-to-target trial, participants [mean (± sd) age 58.9 (±8.9) years, duration of diabetes 9.5 (±5.9) years, HbA1c 68 (±8.7) mmol/mol or 8.4 (±0.8)% and BMI 31.2 (±4.2) kg/m(2) ) were randomized (1:1) to insulin degludec/insulin aspart (n = 197) or biphasic insulin aspart 30 (n = 197), administered with breakfast and the main evening meal, titrated to a self-monitored plasma glucose target > 3.9 and ≤ 5.0 mmol/l. RESULTS: The mean HbA1c was reduced to 49 mmol/mol (6.6%) with insulin degludec/insulin aspart and 48 mmol/mol (6.5%) with biphasic insulin aspart 30. Insulin degludec/insulin aspart achieved the prespecified non-inferiority margin (estimated treatment difference 0.02%; 95% CI -0.12, 0.17). Insulin degludec/insulin aspart was superior in lowering fasting plasma glucose (estimated treatment difference -1.00 mmol/l; 95% CI -1.4, -0.6; P < 0.001) and reducing overall and nocturnal confirmed hypoglycaemia at a similar overall insulin dose compared with biphasic insulin aspart 30. Similar proportions of participants in each arm experienced severe hypoglycaemia. Adverse events were equally distributed. CONCLUSIONS: Consistent with previous findings, insulin degludec/insulin aspart twice daily effectively improved long-term glycaemic control, with superior reductions in FPG, and significantly less overall and nocturnal confirmed hypoglycaemia compared with biphasic insulin aspart 30 in people with Type 2 diabetes who were insulin-naïve.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000976
003      
CZ-PrNML
005      
20170116103649.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/dme.12982 $2 doi
024    7_
$a 10.1111/dme.12982 $2 doi
035    __
$a (PubMed)26435365
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Franek, E $u Mossakowski Medical Research Centre, Polish Academy of Sciences and Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital MSW, Warsaw, Poland.
245    10
$a Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes / $c E. Franek, M. Haluzík, S. Canecki Varžić, M. Sargin, S. Macura, J. Zacho, JS. Christiansen,
520    9_
$a AIM: To evaluate the efficacy and safety of twice-daily insulin degludec/insulin aspart vs. twice-daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naïve to insulin. METHODS: In this 26-week, multinational, open-label, controlled, two-arm, parallel-group, treat-to-target trial, participants [mean (± sd) age 58.9 (±8.9) years, duration of diabetes 9.5 (±5.9) years, HbA1c 68 (±8.7) mmol/mol or 8.4 (±0.8)% and BMI 31.2 (±4.2) kg/m(2) ) were randomized (1:1) to insulin degludec/insulin aspart (n = 197) or biphasic insulin aspart 30 (n = 197), administered with breakfast and the main evening meal, titrated to a self-monitored plasma glucose target > 3.9 and ≤ 5.0 mmol/l. RESULTS: The mean HbA1c was reduced to 49 mmol/mol (6.6%) with insulin degludec/insulin aspart and 48 mmol/mol (6.5%) with biphasic insulin aspart 30. Insulin degludec/insulin aspart achieved the prespecified non-inferiority margin (estimated treatment difference 0.02%; 95% CI -0.12, 0.17). Insulin degludec/insulin aspart was superior in lowering fasting plasma glucose (estimated treatment difference -1.00 mmol/l; 95% CI -1.4, -0.6; P < 0.001) and reducing overall and nocturnal confirmed hypoglycaemia at a similar overall insulin dose compared with biphasic insulin aspart 30. Similar proportions of participants in each arm experienced severe hypoglycaemia. Adverse events were equally distributed. CONCLUSIONS: Consistent with previous findings, insulin degludec/insulin aspart twice daily effectively improved long-term glycaemic control, with superior reductions in FPG, and significantly less overall and nocturnal confirmed hypoglycaemia compared with biphasic insulin aspart 30 in people with Type 2 diabetes who were insulin-naïve.
650    _2
$a senioři $7 D000368
650    _2
$a bifázický inzulin $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D061265
650    _2
$a krevní glukóza $x analýza $7 D001786
650    _2
$a selfmonitoring glykemie $7 D015190
650    _2
$a diabetes mellitus 2. typu $x krev $x farmakoterapie $7 D003924
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a monitorování léčiv $7 D016903
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glykovaný hemoglobin $x analýza $7 D006442
650    _2
$a lidé $7 D006801
650    _2
$a hyperglykemie $x prevence a kontrola $7 D006943
650    _2
$a hypoglykemie $x chemicky indukované $x epidemiologie $x patofyziologie $x prevence a kontrola $7 D007003
650    _2
$a hypoglykemika $x aplikace a dávkování $x škodlivé účinky $x chemie $x terapeutické užití $7 D007004
650    _2
$a inzulin aspart $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D061267
650    _2
$a NPH inzulin $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007336
650    _2
$a dlouhodobě působící inzulin $x aplikace a dávkování $x škodlivé účinky $x chemie $x terapeutické užití $7 D049528
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a jídla $7 D062407
650    _2
$a lidé středního věku $7 D008875
650    _2
$a riziko $7 D012306
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a rozpustnost $7 D012995
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Haluzík, M $u Third Department of Medicine, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Canecki Varžić, S $u Clinical Hospital Center Osijek, Osijek, Croatia.
700    1_
$a Sargin, M $u Kartal Training and Research Hospital, Istanbul, Turkey.
700    1_
$a Macura, S $u Novo Nordisk A/S, Søborg, Denmark.
700    1_
$a Zacho, J $u Novo Nordisk A/S, Søborg, Denmark.
700    1_
$a Christiansen, J S $u Aarhus University Hospital, Aarhus, Denmark.
773    0_
$w MED00001389 $t Diabetic medicine a journal of the British Diabetic Association $x 1464-5491 $g Roč. 33, č. 4 (2016), s. 497-505
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26435365 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170116103753 $b ABA008
999    __
$a ok $b bmc $g 1180116 $s 961543
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 33 $c 4 $d 497-505 $e 20151117 $i 1464-5491 $m Diabetic medicine $n Diabet Med $x MED00001389
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace